Printer Friendly

Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies.

NEW YORK, June 30, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies http://www.reportlinker.com/p02200869/Osteoporosis-Treatment-and-Prevention-World-Drug-Market-Forecast-2014-2024--Future-Prospects-for-Leading-Companies.html

Report Details Treatments for nausea and vomiting - explore business trends, R&D, and revenue forecasts What's the future of treating nausea and vomiting? For those medicines you get sales predictions, also exploring research and development. Those treatments hold high potential. There you assess results, progress, therapies, and opportunities. Visiongain's new report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. Discover business potentials - trends, technologies, and new drugs. Read on to explore anti-nausea and anti-vomiting therapies, seeing their potential revenue.

Forecasts to 2024 and other analyses explain and predict that pharma market Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2024 for those pharmaceuticals. There find results, growth rates, market shares, and discussions. Also you explore research and development (R&D). That study gives 41 tables, 48 charts, and an interview with a company. There find how you could benefit your authority and save time, staying ahead. That study lets you assess the future of treating nausea and vomiting - especially in cancer treatment - exploring rising needs and demands. You find where opportunities and money lie. See, from 2014, where best selling prospects exist. And the following sections show how that new investigation benefits your research, analyses and decisions.

Forecasting of that world market and its main segments In our report you discover overall world revenue to 2024 for antiemetic medicines, with discussions. You also find individual revenue predictions to 2024 for four submarkets at world level - drug classes: -- 5-HT3 antagonists -- Cannabinoids -- Dopamine antagonists -- Other agents (grouped). There you assess outlooks for expansion in trade, hearing where you could gain. That work investigates therapies, uses, and rising sales. Our study also explores competition. There you hear what's happening for developers, producers, and sellers of antiemetic agents, understanding challenges, trends, and rising sales. That work also splits its overall world market into products.

Predictions of leading treatments' sales How will drugs perform to 2024 at world level? Our study forecasts individual revenues of eight top products: -- Palonosetron -- Ondansetron -- Granisetron -- Dolasetron -- Dronabinol -- Nabilone -- Metoclopramide -- Domperidone. There you find medicines and years with highest predicted sales. You also examine competitors. See, then, what's happening, understanding, challenges, trends, and outlooks. The new study also gives geographical revenue predictions.

Healthcare in national markets - what outlooks for that business? In developed and developing countries, many opportunities for developers, producers, and sellers of antiemetic medicines will occur from 2014 to 2024. See where and how. Our analyses show individual revenue forecasts to 2024 for 11 national markets: -- United States (US) -- Japan -- Germany, France, UK, Italy, and Spain (EU5) -- Brazil, Russia, India, and China (BRIC nations). There you find countries with highest revenues, demand, and potential sales growth. Explore progress, needs and opportunities. Also what events, challenges and advances in technology affect that industry and market? Our work shows you, discussing progress, policies, and R&D.

Market forces and issues - developments, challenges, and events influencing business The report also explains issues, forces, and events affecting the antiemetic drugs industry and market from 2014, including these: -- Emesis and its pharmacological management - pathways and targets -- Future of serotonin (5-HT3) antagonists - existing and new therapies -- Demand for antiemetics in post-operative settings, inc. cancer and other diseases -- Drug delivery to improve patient compliance. And you assess these trends and influences, among others: -- Improvements in design of clinical trials for those treatments -- Effects of investments in healthcare, esp. in emerging countries -- Improvements to therapy, inc. using antihistamines and prolonging drug action -- Efforts to develop new drugs - R&D harnessing new receptors and mechanisms of action, with emerging technologies. There you explore political, economic, social, and technological questions, as well as strengths weaknesses, opportunities, and threats. Discover what the future holds. See, too, how R&D helps companies benefit patients and expand that market. You find, then, what stimulates and restrains firms in that sector, affecting its results.

Antiemetic medicines - opportunities and 2018 market value Our study predicts that overall world market will reach $4.6bn in 2018, with further expansion to 2024. There large pharmaceutical corporations and specialty companies can gain. See how. From 2014 to 2024 that industry holds many opportunities. And you examine its technological and commercial possibilities, staying ahead in knowledge.

Ways Antiemetic Drugs: World Industry and Market Analysis 2014-2024 helps In these main ways, that investigation helps your work: -- Revenues to 2024 at world level, for 4 submarkets, and 8 leading products - assess outlooks for production, marketing, and sales -- Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - investigate countries for revenues and sales expansion -- Prospects for established competitors, rising companies, and new entrants - explore portfolios, results, actions, R&D, and outlooks for success.

Knowledge there found nowhere else, benefiting your searches, analyses, and planning Our work gives independent analysis. There you receive business intelligence found only in our report, seeing where prospects are most rewarding.

1. Overview of Report 1.1 Antiemetic Drug Treatments: World Market Review 1.2 Content of Report Chapters 1.3 Research and Analysis Methods

2. Introduction to Emesis and Antiemetic Drugs 2.1 What is Emesis? 2.1.1 The Process of Emesis: The Role of the Vomiting Centre 2.2 Causes and Complications of Vomiting Vary 2.2.1 Most Common Triggers of Vomiting 2.3 Diagnosing Emesis: Multidisciplinary Approach Required 2.4 Treating Emesis and the Approach to Pharmacological Management 2.4.1 Serotonin (5-HT3) Antagonists: Gold Standard Treatment 2.4.2 Cannabinoids: Controversial Choice, But Interest Remains 2.4.3 Dopamine Antagonists: Effective in Post-Operative Setting 2.4.4 Other Therapies

3. The Global Antiemetic Drug Market, 2014-2024 3.1 The Global Antiemetic Drug Market, 2013 3.1.1 Leading Antiemetic Drugs, 2013 3.2 The Global Antiemetic Drug Market: Revenue Forecast, 2014-2024 3.2.1 What Will Drive The Global Antiemetic Drug Market Between 2014 and 2024? 3.2.1.1 Growing Incidence of Cancer and Other Diseases 3.2.1.2 Increased Research Efforts Focused on New Therapies 3.2.1.3 Identifying New Drug Targets Through Technology 3.2.1.4 Launch of Novel Delivery Methods to Encourage Patient Compliance 3.2.2 What Factors are Likely to Restrain the Global Antiemetic Drug Market Between 2014 and 2024? 3.2.2.1 Improvements Needed in Design of Antiemetic Clinical Trials 3.2.2.2 High Cost of Alternative Animal Models 3.3 How Will the Market Shares of Leading Antiemetic Drug Classes Change From 2014-2024?

4. The 5-HT3 Antagonists Drug Market, 2014-2024 4.1 The 5-HT3 Antagonists Drug Market, 2013 4.2 The 5-HT3 Antagonists Drug Market: Revenue Forecast, 2014-2024 4.2.1 The 5-HT3 Antagonists Drug Market: Industry Trends, 2014-2024 4.3 The 5-HT3 Antagonists Drug Market: Revenue Forecasts of Leading Drugs, 2014-2024 4.3.1 Palonosetron (Aloxi): Revenue Forecast, 2014-2024 4.3.2 Ondansetron (Zofran): Revenue Forecast, 2014-2024 4.3.3 Granisetron (Sancuso): Revenue Forecast, 2014-2024 4.3.4 Dolasetron (Anzemet): Revenue Forecast, 2014-2024 4.4 How Will Market Shares of Leading 5-HT3 Antagonist Drugs Change from 2014-2024?

5. The Cannabinoids Drug Market, 2014-2024 5.1 The Cannabinoids Drug Market, 2013 5.2 The Cannabinoids Drug Market: Revenue Forecast, 2014-2024 5.2.1 The Cannabinoids Drug Market: Industry Trends, 2014-2024 5.3 The Cannabinoids Drug Market: Revenue Forecast by Leading Drugs, 2014-2024 5.3.1 Dronabinol (Marinol): Revenue Forecast, 2014-2024 5.3.2 Nabilone (Cesamet): Revenue Forecast, 2014-2024 5.4 How Will the Market Shares of Leading Cannabinoid Drugs Change from 2014-2024?

6. The Dopamine Antagonists Drug Market, 2014-2024 6.1 The Dopamine Antagonists Drug Market, 2013 6.2 The Dopamine Antagonists Drug Market: Revenue Forecast, 2014-2024 6.2.1 The Dopamine Antagonists Drug Market: Industry Trends, 2014-2024 6.3 The Dopamine Antagonists Drug Market: Revenue Forecast by Leading Drugs, 2014-2024 6.3.1 Metoclopramide (Reglan): Revenue Forecast, 2014-2024 6.3.2 Domperidone (Motilium): Revenue Forecast, 2014-2024 6.4 How Will Market Shares of Leading Dopamine Antagonist Drugs Change from 2014-2024?

7. Leading National Markets for Antiemetic Drugs, 2014-2024 7.1 Leading National Markets for Antiemetic Drugs, 2013 7.2 The Global Antiemetic Drug Market: Revenue Forecasts by Region, 2014-2024 7.3 The US Antiemetic Drug Market: Revenue Forecast, 2014-2024 7.3.1 Novel Drug Formulation to Increase Compliance 7.4 The Antiemetic Drug Market in Leading EU Countries (EU5), 2013 7.4.1 The Antiemetic Drug Market in the EU5: Revenue Forecasts by Country, 2014-2024 7.4.1.1 The German Antiemetic Drug Market: Revenue Forecast, 2014-2024 7.4.1.2 The French Antiemetic Drug Market: Revenue Forecast, 2014-2024 7.4.1.3 The UK Antiemetic Drug Market: Revenue Forecast, 2014-2024 7.4.1.4 The Italian Antiemetic Drug Market: Revenue Forecast, 2014-2024 7.4.1.5 The Spanish Antiemetic Drug Market: Revenue Forecast, 2014-2024 7.5 The Japanese Antiemetic Drug Market: Revenue Forecast, 2014-2024 7.6 The Russian Antiemetic Drug Market: Revenue Forecast, 2014-2024 7.7 The Chinese Antiemetic Drug Market: Revenue Forecast, 2014-2024 7.7.1 Strong Incentives Prompt Entry of New Companies 7.7.2 Multi-Billion Dollar Investment to Improve Healthcare 7.8 The Indian Antiemetic Drug Market: Revenue Forecast, 2014-2024 7.8.1 Difficulties in Drug Distribution May Restrict Market 7.9 The Brazilian Antiemetic Drug Market: Revenue Forecast, 2014-2024 7.9.1 Restrictions on Foreign Companies May Stifle Market Growth

8. The Antiemetic Drug Market: R&D Pipeline, 2014 8.1 Discovering New Treatments and Molecular Targets 8.2 Targeting Serotonin: Expanding on the Clinical Success of 5-HT3 Antagonists 8.2.1 Sustol (APF-530; Heron Therapeutics): Enhanced Duration of Action 8.2.2 RHB-102 (RedHill Biopharma): Consistent Bioequivalency with Marketed Therapy 8.2.3 ETI-385 (Epiomed): Aiming to Target Multiple Emesis Pathways 8.3 Cannabinoids: R&D Pipeline Developments 8.3.1 Dronabinol Oral Solution (INSYS Therapeutics): Improved Bioavailability 8.4 Dopamine Antagonists: R&D Pipeline Developments 8.4.1 APD421 (Acacia Pharma): New Indication for Drug? 8.4.2 APD403 (Acacia Pharma): Potential Market Leader? 8.5 Other Novel Drugs Under Development 8.5.1 NK1 Receptor Antagonists 8.5.1.1 Netupitant-Palonosetron (Helsinn Healthcare): Dual Drug Combination 8.5.1.2 Rolapitant (OPKO Health/TESARO): Therapy Offering Prolonged, 5-day Effect 8.5.1.3 Vestipitant (GW597599; GSK): Applications in Numerous Therapeutic Areas? 8.5.2 Antihistamines 8.5.2.1 CL-108 (Charleston Laboratories): Targeting Emesis and Pain 8.5.3 Non-Pharmacological Therapies 8.5.3.1 Zindol (Aphios Corporation): Ginger-based Therapy

9. World Antiemetic Drug Market: Industry Trends, 2014-2024 9.1 SWOT Analysis of the Global Antiemetic Drug Market, 2014-2024 9.2 Strengths 9.2.1 The Drive to Discover a Universal Therapy 9.2.2 Varied Market Landscape Containing Big and Small Players 9.3 Weaknesses 9.3.1 Antiemetic Trials Need Overhaul 9.4 Opportunities 9.4.1 Global Increase in Cancer Prevalence 9.4.2 Secondary Indications Encourage Companies to Enter Market 9.5 Threats 9.5.1 Concerns of Cardiac Side Effects of Market-Leading Drugs 9.5.2 Wearable Devices: Stimulating Neural Emesis Pathways 9.6 STEP Analysis of the Global Antiemetic Drug Market, 2014-2024 9.6.1 Social Factors 9.6.2 Technological Advances 9.6.3 Economic Pressures 9.6.4 Political Issues

10. Research Interview 10.1 Interview with a Respondent from a Company Marketing Antiemetic Therapies 10.1.1 The Current Antiemetic Drug Market and Demand in the Asia-Pacific Region 10.1.2 Market Competition and Common Diseases Triggering Emesis 10.1.3 Current and Future Directions for Antiemetic Therapy

11. Conclusions 11.1 The Global Antiemetic Drug Market - Current Status 11.2 Outlook for the Global Antiemetic Drugs Market, 2014-2024 11.2.1 5-HT3 Antagonists Will Continue to Dominate the Market 11.2.2 Regional Outlook for the Antiemetic Drugs Market, 2014-2024

List of Tables Table 1.1 Common Abbreviations Used in this Report Table 2.1 Commonly Prescribed Antiemetic Medications, 2014 Table 3.1 The Global Antiemetic Drug Market: Revenue ($m) and Market Share (%) by Drug Class, 2013 Table 3.2 Leading Antiemetic Drugs: Revenue ($m) and Market Share (%) by Drug, 2013 Table 3.3 The Global Antiemetic Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Drug Class, 2014-2024 Table 3.4 The Global Antiemetic Market: Market Shares (%) by Drug Class, 2014-2024 Table 4.1 The 5-HT3 Antagonists Drug Market: Revenue ($m) and Market Share (%) by Leading Drug, 2013 Table 4.2 The 5-HT3 Antagonists Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Leading Drug, 2014-2024 Table 4.3 Palonosetron: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 4.4 Ondansetron: Revenue Forecast ($m, AGR, CAGR %), 2014-2024 Table 4.5 Granisetron: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 4.6 Dolasetron: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 4.7 The 5-HT3 Antagonists Drug Market: Market Shares (%) by Drug, 2014-2024 Table 5.1 The Cannabinoids Drug Market: Revenue ($m) and Market Shares (%) by Leading Drug, 2013 Table 5.2 The Cannabinoids Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Leading Drug, 2014-2024 Table 5.3 Dronabinol: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 5.4 Nabilone: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 5.5 The Cannabinoids Drug Market: Market Share (%) by Drug, 2014-2024 Table 6.1 The Dopamine Antagonists Drug Market: Revenues ($m) and Market Shares (%) by Leading Drug, 2013 Table 6.2 The Dopamine Antagonists Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Leading Drug, 2014-2024 Table 6.3 Metoclopramide: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 6.4 Domperidone: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 6.5 The Dopamine Antagonists: Market Shares (%) by Drug, 2014-2024 Table 7.1 The Global Antiemetic Drug Market: Revenues ($m) and Market Shares (%) by Region, 2013 Table 7.2 The Global Antiemetic Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) by Region, 2014-2024 Table 7.3 The US Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 7.4 The EU5 Antiemetic Drug Market: Revenue ($m), EU5 Market Share (%) and Global Market Share (%) by Country, 2013 Table 7.5 The EU5 Antiemetic Drug Market: Revenue Forecasts ($m, AGR %, CAGR %) for Leading Countries, 2014-2024 Table 7.6 The German Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 7.7 The French Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 7.8 The UK Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 7.9 The Italian Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 7.10 The Spanish Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 7.11 The Japanese Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 7.12 The Russian Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 7.13 The Chinese Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 7.14 The Indian Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 7.15 The Brazilian Antiemetic Drug Market: Revenue Forecast ($m, AGR %, CAGR %), 2014-2024 Table 9.1 SWOT Analysis of the World Antiemetic Drugs Market, 2014-2024 Table 11.1 The World Antiemetic Drugs Market: Revenue Forecasts ($m, AGR %, CAGR %) and Market Shares (%) by Drug Class, 2013, 2018 and 2024 Table 11.2 The World Antiemetic Drugs Market: Revenue Forecasts ($m, AGR %, CAGR %) and Market Shares (%) by Region, 2013, 2018 and 2024

List of Figures Figure 3.1 The Global Antiemetic Drug Market: Revenue ($m) by Drug Class, 2013 Figure 3.2 The Global Antiemetic Drug Market: Market Shares (%) by Drug Class, 2013 Figure 3.3 Leading Antiemetic Drugs: Market Share (%) by Drug, 2013 Figure 3.4 The Global Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 3.5 The Global Antiemetic Drug Market: Drivers and Restraints, 2014-2024 Figure 3.6 The Global Antiemetic Drug Market: Market Shares (%) by Drug Class, 2018 Figure 3.7 The Global Antiemetic Drug Market: Revenue Shares (%) by Drug Class, 2024 Figure 4.1 The 5-HT3 Antagonists Drug Market: Revenue ($m) by Leading Drug, 2013 Figure 4.2 The 5-HT3 Antagonists Drug Market: Market Shares (%) by Leading Drug, 2013 Figure 4.3 The 5-HT3 Antagonists Drug Market: Revenue Forecast ($m), 2014-2024 Figure 4.4 Palonosetron: Revenue Forecast ($m), 2014-2024 Figure 4.5 Ondansetron: Revenue Forecast ($m), 2014-2024 Figure 4.6 Granisetron: Revenue Forecast ($m), 2014-2024 Figure 4.7 Dolasetron: Revenue Forecast ($m), 2014-2024 Figure 4.8 The 5-HT3 Antagonists Drug Market: Market Shares (%) by Drug, 2018 Figure 4.9 The 5-HT3 Antagonists Drug Market: Market Shares (%) by Drug, 2024 Figure 5.1 The Cannabinoids Drug Market: Revenue ($m) by Leading Drug, 2013 Figure 5.2 The Cannabinoids Drug Market: Market Shares (%) by Leading Drug, 2013 Figure 5.3 The Cannabinoids Drug Market: Revenue Forecast ($m), 2014-2024 Figure 5.4 Dronabinol: Revenue Forecast ($m), 2014-2024 Figure 5.5 Nabilone: Revenue Forecast ($m), 2014-2024 Figure 5.6 The Cannabinoids Drug Market: Market Shares (%) by Drug, 2018 Figure 5.7 The Cannabinoids Drug Market: Market Shares (%) by Drug, 2024 Figure 6.1 The Dopamine Antagonists Drug Market: Revenues ($m) by Leading Drug, 2013 Figure 6.2 The Dopamine Antagonists Drug Market: Market Shares (%) by Leading Drug, 2013 Figure 6.3 The Dopamine Antagonists Drug Market: Revenue Forecast ($m), 2014-2024 Figure 6.4 Metoclopramide: Revenue Forecast ($m), 2014-2024 Figure 6.5 Domperidone: Revenue Forecast ($m), 2014-2024 Figure 6.6 The Dopamine Antagonists Drug Market: Market Shares (%) by Drug, 2018 Figure 6.7 The Dopamine Antagonists Drug Market: Market Shares (%) by Drug, 2024 Figure 7.1 The Global Antiemetic Drug Market: Revenue ($m) by Region, 2013 Figure 7.2 The Global Antiemetic Drug Market: Market Shares (%) by Region, 2013 Figure 7.3 The US Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 7.4 The EU5 Antiemetic Drug Market: Revenue ($m) by Country, 2013 Figure 7.5 The EU5 Antiemetic Drug Market: Market Shares (%) by Country, 2013 Figure 7.6 The EU5 Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 7.7 The German Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 7.8 The French Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 7.9 The UK Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 7.10 The Italian Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 7.11 The Spanish Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 7.12 The Japanese Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 7.13 The Russian Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 7.14 The Chinese Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 7.15 The Indian Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 7.16 The Brazilian Antiemetic Drug Market: Revenue Forecast ($m), 2014-2024 Figure 11.1 The Global Antiemetic Drug Market: Revenue Forecasts ($m) by Drug Class, 2013, 2018 and 2024 Figure 11.2 The Global Antiemetic Drug Market: Revenue Forecasts ($m) by Region, 2013, 2018 and 2024

Companies Listed Acacia Pharma American Society of Clinical Oncology Aphios Corporation Aptalis Pharma Astra Zeneca Charleston Laboratories Eisai Epiomed Therapeutics European Medicines Agency (EMA) Food and Drug Administration (FDA) GlaxoSmithKline (GSK) Helsinn Healthcare Heron Therapeutics INSYS Therapeutics Italian Group for Clinical Research (G.O.I.R.C) MacMillan Cancer Care Merck and Co. MHRA (Medicines and Healthcare Products Regulatory Agency) Multinational Association of Supportive Care in Cancer Mundipharma N.N. Petrov Institute of Oncology National Government Services (NGS) Neurowave Medical Technologies OPKO Health ProStrakan RedHill Biopharma Roche Schering Plough Corporation Schwarz Pharma SCOLR Pharma TESARO Vifor Pharma

To order this report: Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies http://www.reportlinker.com/p02200869/Osteoporosis-Treatment-and-Prevention-World-Drug-Market-Forecast-2014-2024--Future-Prospects-for-Leading-Companies.html

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker
COPYRIGHT 2014 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 2014
Words:3501
Previous Article:Interop New York To Demonstrate SDN Capabilities in Multi-Vendor InteropNet Test Lab.
Next Article:Health Care District of Palm Beach County Marks 25 Years Of Service.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters